Integral Health Asset Management LLC Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Integral Health Asset Management LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 50,000 shares of the medical equipment provider’s stock, valued at approximately $3,712,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after acquiring an additional 2,753,016 shares during the period. Black Creek Investment Management Inc. raised its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after acquiring an additional 885,524 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Hologic by 4.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after acquiring an additional 87,176 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquiring an additional 1,168,564 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 18th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Trading Down 1.2 %

NASDAQ HOLX opened at $81.39 on Monday. The firm has a 50 day moving average of $80.82 and a two-hundred day moving average of $77.13. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $18.99 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the business posted $0.93 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, research analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.